Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.

Abstract

These data suggest that anomalies of beta-catenin expression occur in PrCa and that these anomalies are associated with disease progression, especially to the therapeutic-resistant state.